Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxidized regenerated cellulose (ORC) is an absorbable, synthetic mechanical barrier used to prevent postoperative adhesions and provide hemostasis. It is produced through the controlled oxidation of cellulose, resulting in a material that can be placed between surgical surfaces to physically separate them during the initial stages of wound healing. In a clinical trial conducted by National Taiwan University Hospital, ORC was evaluated for its efficacy in reducing post-thyroidectomy adhesions, which can cause neck discomfort, dysphagia, and skin-to-trachea tethering. The material is typically absorbed by the body within approximately two weeks, minimizing long-term foreign body reactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxidized regenerated cellulose.